The relationship between lesion density change in chest computed tomography and clinical improvement in COVID-19 patients

Isil Yurdaisik1 | Fuad Nurili2 | Ayse Gul Agirman3 | Suleyman Hilmi Aksoy4

1Department of Radiology, Istinye University, Gaziosmanpasa Medical Park Hospital, Istanbul, Turkey
2Department of Radiology, Memorial Sloan Kettering Cancer Center, Interventional Radiology, New York, NY, USA
3Department of Radiology, Dr. Sıyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey
4Department of Radiology, Galata University, Hisar Intercontinental Hospital, Istanbul, Turkey

Abstract

Objective: To evaluate the association of changes in chest computed tomography (CT) lesion densities with clinical improvement in COVID-19 patients.

Methods: This was a cross-sectional analysis of hospitalised COVID-19 patients who underwent repeated chest CT. Patients who improved clinically but showed radiological progression were included. Demographic data, presentation complaints and laboratory results were retrieved from the electronic database of the hospital. Lesion density that was measured in Hounsfield units was compared between admission and discharge chest CT scans.

Results: Forty patients (21 males, mean age 47.4 ± 15.1 years) were included in the analysis. The median white blood cell count and C-reactive protein significantly decreased, whereas the median lymphocyte count significantly increased at discharge compared with the admission values. The mean density significantly reduced from admission to discharge.

Conclusion: This is the first study in the literature reporting reduction in chest CT lesion densities correlated with clinical and laboratory improvement in COVID-19 patients.

1 | INTRODUCTION

SARS-CoV-2 is a novel coronavirus that led to a pandemic and claimed more than 550 thousand lives worldwide as of July 2020. The virus causes acute respiratory stress syndrome (ARDS) in about 30% of the patients.1 Although the fatality rates were lower than those of Middle East respiratory virus and SARS-CoV, lack of an efficient treatment makes the early detection and preventive measures the foremost priority to prevent spreading. Currently, the diagnosis of the condition is most commonly based on the detection of the SARS-CoV-2 from respiratory samples via reverse transcription-polymerase chain reaction (RT-PCR) method. However, several studies reported the positivity rates of the test between 32% and 93% depending upon the method of sample acquisition.2 Thus, despite suggestive clinical findings and a positive history of epidemiologic exposure to COVID-19, some patients have a negative RT-PCR test. In these patients, chest CT findings might provide supportive evidence for the diagnosis of COVID-19.3,4

On the other hand, the radiologic appearance of the COVID-19 lung disease shows an evolution through time and somehow lags behind the clinical improvement. Several studies defined chest CT stages based on the time from the symptom onset. In stage 4 (>14 days after first symptoms), 65% and 75% of patients still had ground-glass opacities (GGOs) and consolidation on chest CT images, respectively.2 It is clear that more time is needed to observe the complete resolution of lung abnormalities. Thus, if one depends solely on the chest CT characteristics for treatment change or discharge decisions, it would be misleading. It was hypothesized that chest CT lesion densities might provide us with valuable information regarding the improvement of the lesions. When combined with clinical improvement of the patient, chest CT densities, measured in Hounsfield units, might serve as an adjunctive measure whether a patient is ready for discharge.
Hence, it was decided to evaluate the association of the change in the chest CT lesion densities with clinical improvement in COVID-19 patients whose chest CT lesions persisted or worsened.

2 | MATERIALS AND METHODS

2.1 | Study participants, design and setting

This study was a cross-sectional analysis of COVID-19 patients who underwent repeated chest computed tomography (CT) during their hospitalisation. Study subjects were diagnosed with COVID-19 by means of RT-PCR technique, or the diagnosis was based on compatible clinical and pulmonary radiological evidence of COVID-19. COVID-19 patients who presented to the emergency department of our pandemic hospital and were hospitalised between 15 March and 1 April 2020 were enrolled. During this period, a total of 326 patients were hospitalised because of COVID-19. Of these patients, only 189 patients (57.9%) had a positive RT-PCR test for SARS-CoV-2.

A repeat chest CT was performed before discharge in all study subjects, irrespective of their clinical status. Patients aged below 18 years, those who had no an RT-PCR positive COVID-19 diagnosis, patients who were still staying in the hospital, those who did not show clinical improvement, patients with chest CT findings not caused by COVID-19, those who had lesions other than GGOs that may affect density measurements, moderate to severe pleural effusion and patients with GGO that occupied a small area were excluded from the study. After the exclusion of the patients due to the aforementioned reasons, a total of 77 patients with COVID-19 remained. Of these, 37 patients were excluded because they showed clinical improvement along with radiologic improvement. The remaining 40 patients who improved clinically but showed radiological progression were included in the analyses. The study flowchart is seen in Figure 1.

Study protocol was approved by the local ethics committee of our hospital (2/2020.K-025). The objectives of the study were explained to all patients, and written informed consents were signed by the study participants. The study was performed in accordance with the ethical principles of the Declaration of Helsinki.

2.2 | Data collection

Data, including patient sex, age, presentation complaints and laboratory results (complete blood count, basic biochemistry tests, procalcitonin, ferritin, D-dimer and troponin I) were retrieved from the electronic database of the hospital and recorded for each participant.

2.3 | Acquisition of the chest CT images

Because of the COVID-19 pandemic, every necessary measure was taken to prevent the spread of the disease via the imaging procedure.

What’s known
- The radiologic appearance of the COVID-19 lung disease shows an evolution through time and somehow lags behind the clinical improvement.
- More time is needed to observe the complete resolution of lung abnormalities.
- If one depends solely on the chest CT characteristics for treatment change or discharge decisions, it would be misleading.

What’s new
- This study reports for the first time in the literature that reduction in chest CT lesion densities correlated with clinical and laboratory improvement in patients hospitalised because of COVID-19.
- Chest CT density reduction might point to the future resolution of the lung lesions and may preclude unnecessarily long hospitalisations due to this disease.
- This is of practical importance considering the limited inpatient bed capacities in some parts of the world.

All patients who would undergo chest CT imaging were instructed to wear a face mask during the whole procedure. Disposable bed sheets were used during each examination, and all used equipment and room were thoroughly disinfected after each scan. Radiology staff wore a face mask, disposable gloves, and gowns and safety goggles during the patient admission and image acquisition.

Chest CT scans were performed with a 128-slice multidetector CT scanner (Somatom Definition AS+ Erlangen, Germany). During each scan, the following standard parameters were used: slice thickness of 1.0 mm, reconstruction interval of 1.0-3.0 mm, tube voltage of 120 kVp, and automatic exposure controlled standard tube flow. The patients were imaged on the axial plane, in the supine position, and during end-inspiration.

2.4 | Analysis of the chest CT images

All chest CT scans of the study subjects were evaluated by the same experienced radiologist. For each patient, the chest CT at hospitalisation (admission chest CT) and the chest CT performed before discharge (discharge chest CT) were evaluated. Progression of the COVID-19 lung disease was assessed by comparing the extent, amount and density of the lesions detected on the initial and repeat chest CT scans. Fusion of the lesions, development of new lesions, and increase in lesion density were considered as progression. On the other hand, a decrease in lesion density was accepted as absorption.

Lesion density that was measured in Hounsfield units (HU) was compared between admission and discharge chest CT scans. This
analysis was performed only in lesions with ground-glass appearance. No measurement was made in other lesions composed of consolidation, air bronchograms, pleuro-parenchymal band, air cyst etc. A fixed region of interest (ROI, mm²) was used for the purpose of area measurements. The ROI was determined circular or oval, depending on the shape of the target lesion. Great attention was paid to that ROIs had the same size and shape as much as possible in the initial and repeat CT scans. The repeat measurements were taken from the same lesion and anatomic location of the initial chest CT scan.

2.5 Statistical analysis

The Shapiro–Wilks test was used to check the normality assumptions of the data. Normally distributed variables were presented as a mean ± standard deviation, whereas non-normally distributed variables were given as median and interquartile range. Paired sample t test was used for normally distributed numerical variables in two-group comparisons in paired data. For variables that were not normally distributed, the Wilcoxon signed-rank test was used. To compare paired nominal data, the McNemar’s test was used. SPSS 25.0 software package (IBM, Armonk, NY, USA) was used to analyse data of the study. A P value of <.05 was accepted as statistically significant.

3 RESULTS

After exclusion criteria were applied, 40 patients (21 males, 52.5%) were included in the final analysis. The mean age of the patients was 47.4 ± 15.1 years (range 20-70 years). Fever and cough were the most common symptoms and were present in all patients (100%). Fever, dyspnea and cough were present at discharge evaluation in 12.5%, 17.5% and 62.5% of the patients, respectively. The frequency of all symptoms decreased significantly at discharge evaluation compared with admission. Table 1 shows age and sex distribution, frequency of admission and discharge symptoms and some laboratory findings of the study subjects.

The median white blood cell count significantly decreased, whereas the median lymphocyte count significantly increased at discharge compared with the admission values. At discharge evaluation, three patients had mild leucopenia, while the rest of the patients had normal white blood cell counts. The median platelet count showed a significant increase at discharge compared with the admission value. The median C-reactive protein (CRP) value on admission significantly reduced at discharge, from 2.45 (IQR: 1.33-4.0) to 0.25 (IQR: 0.2-0.4). There was no significant change in procalcitonin levels between the admission and discharge. The laboratory parameters of COVID-19 patients on admission and at discharge are depicted in Table 2.
The mean duration between the admission and discharge CT scans was 5.8 ± 1.30 (min–max: 4-10) days. The mean lesion density of the ROI comprising ground-glass opacities was −292.1 ± 177.1 (min: −579 and max: +239) on admission. On admission chest CT measurements, two (5%) patients had a positive lesion density value, while the rest of the patients (95%) had negative densities. At discharge CT, the mean density was −418.9 ± 162.7 (min: −773 and max: −156). All patients had negative density values at discharge chest CT. The mean density significantly reduced from admission to discharge. The mean decrease in the lesion densities was found to be 129.9 ± 79.02 (min–max: 11-295) HU. Three chest CT scan examples demonstrating the decrease in lung lesion densities are shown in Figures 2-4.

4 | DISCUSSION

The main objective of the present study was to evaluate whether the changes in the density of the chest CT lung lesions in hospitalised COVID-19 patients provide a clue for disease improvement despite persisting or worsening lung lesions. The density measurements were taken from the GGOs in each patient. All patients had significant clinical improvement throughout the hospitalisation.

Increased lesion density was associated with the progression of the COVID-19 infection. In a study by Li et al,6 increased lesion density along progression of the disease was found in 69% of patients. In the present study, the median chest CT GGO density significantly reduced from the admission to the discharge. This might provide guidance for the practicing physician that although the number and size of the lesions were increased, the reduction in the density of the lesions was correlated with clinical improvement of the patients.

Chest CT imaging is important in the diagnosis of COVID-19. In a meta-analysis of 2738 cases, the authors reported the pooled positivity rate of COVID-19 as 89.8% with CT scans.7 On the other hand, the sensitivity of the first RT-PCR test for COVID-19 was reported as 71%.8 Moreover, patients with false-negative RT-PCR test might still have abnormalities in chest CT imaging.4

The most common presenting lesions on chest CT of these patients, in general, include bilateral peripheral GGOs, seen along with consolidation in some cases.2 Chest CT findings show a predictable evolution with time in COVID-19. The maximum lung involvement was reported to occur at 10 days after symptom onset.9

### TABLE 1

Demographic characteristics, presenting symptoms (during admission and at discharge) and some laboratory values of study participants

| Parameters | Admission (n = 40) | Discharge (n = 40) | P value |
|------------|-------------------|-------------------|---------|
| Age (mean ± SD) (years) | 47.4 ± 15.1 | – | – |
| Sex (n, %) | – | – | – |
| Female | 19 (47.5) | – | – |
| Male | 21 (52.5) | – | – |
| Fever (n, %) | 40 (100) | 5 (12.5) | <.001a |
| Dyspnea (n, %) | 36 (90) | 7 (17.5) | <.001a |
| Cough (n, %) | 40 (100) | 25 (62.5) | <.001a |
| Diarrhoea (n, %) | 5 (12.5) | 7 (17.5) | .063a |
| Myalgia (n, %) | 34 (85.5) | 22 (5) | .025a |
| Ferritin (median, IQR) (ng/mL) | 355 (259.3-452.3) | – | – |
| Troponin (median, IQR) | 5.4 (3.4-7.95) | – | – |
| D-dimer (median, IQR) (ng/mL) | 557 (250.5-2319.8) | – | – |

Abbreviations: IQR, interquartile range; SD, standard deviation.

### TABLE 2

Comparison of the changes in the lesion density (Hounsfield units) and some laboratory values on admission and at discharge

| Parameters | Admission (n = 40) | Discharge (n = 40) | P value |
|------------|-------------------|-------------------|---------|
| Lesion density (Hounsfield units) | −292.1 ± 177.1 | −418.9 ± 162.7 | <.001a |
| WBC (mean ± SD) (×10^3/µL) | 7.89 ± 3.59 | 5.6 ± 1.24 | <.001a |
| Platelet count (mean ± SD) (×10^3/µL) | 299.6 ± 103.4 | 355.7 ± 75.5 | .002a |
| Lymphocyte count (median, IQR) (×10^3/µL) | 1.1 (0.9-1.3) | 2.65 (1.83-3.75) | <.001b |
| spO2 (median, IQR) (%) | 86 (82.5-88) | 94 (92-94) | <.001b |
| CRP (median, IQR) (mg/L) | 2.45 (1.33-4.0) | 0.25 (0.2-0.4) | <.001b |
| Procalcitonin (median, IQR) (µg/L) | 0.3 (0.2-0.48) | 0.2 (0.13-0.48) | .963b |
| ALT (median, IQR) (U/L) | 45 (22-95.3) | 44 (34-45) | .017b |

Abbreviations: ALT, alanine aminotransferase; CRP, C-reactive protein; SD, standard deviation; spO2, oxygen saturation; WBC, white blood cell count.

4a Paired samples t test was used.

4b Wilcoxon signed-rank test was used.
These lesions increase in frequency during the intermediate stage (3-5 days after symptom onset). The late phase is generally defined as 6-12 days after the symptom onset. In this phase, most patients still continue to have lung lesions, most common of which is GGO. Beyond 14 days is defined as the absorption stage, and 65% and 75% of COVID-19 patients have GGO and consolidation, respectively. In our study, the mean duration between admission and discharge was 5.8 days. All patients had negative density values at discharge chest CT, and the mean decrease in lesion density was found as 129.9 ± 79.02 HU.

A considerable number of patients still had persistent lung lesions when they were ready to be discharged based on their clinical condition. Wang and colleagues reported that 94% of their 70 patients still had residual lung lesions on their discharge chest CT images. The most commonly seen lesion was GGOs with a median follow-up duration of 18 days (range 5-43 days) in that study. In another study by Du et al at discharge chest CT images, the most common lesion was GGOs (in 79% of the patients). Thus, chest CT findings solely on the ground of lesion number and size increase in the previous lesions are seen. A close anatomical location and area were used (56.8/63.7 mm²). No visible density difference is observed.
extent might be misleading in the decision-making process of COVID-19 patients.

It was decided to evaluate the density in the GGO lesions because both in the early and late phases of the COVID-19, GGOs were the most commonly observed lesions. All patients included in the present study clinically improved. However, persistence or worsening of the lung lesions on chest CT images was also observed. Despite this, densities of GGOs significantly reduced in all patients at discharge compared to the admission values.

Lesion densities on chest CT images have scarcely been studied in COVID-19. Wang and colleagues did a quantitative analysis of chest CT images to be able to predict the development of ARDS in COVID-19. They included the volume and the density of the target lesion in their deep network analysis. The authors reported that the patients with lesion densities between −549 and −450 HU were at increased risk, while patients with lesion densities between −149 and −50 HU had a reduced risk for ARDS development. On the other hand, neither average density nor the total volume of the lesions was associated with ARDS risk in that study. Du et al. evaluated chest CT findings in a cohort of ready to be discharged COVID-19 patients with the assistance of an artificial intelligence system. The authors revealed that the lesion densities reduced significantly in all patients (100%) at follow-up chest CTs that were performed after the discharge (average time 2-13 days) compared with discharge CTs. The authors actually extended the results of our results. In the present study, it was demonstrated that the density of the lesions significantly decreased from the hospital admission until the discharge. Thus, we think that lesion density decrease despite a seemingly persistent or worsening chest CT image may be a harbinger that the lungs are recovering.

On the other hand, the shortcomings of the chest CT imaging in COVID-19 patients should be taken into account. It is now well known that chest CT images might be normal, particularly in early disease. Several studies reported that in RT-PCR-proven COVID-19, false-negative CT rates might occur up to 56% of the procedures. Besides, chest CT findings are not COVID-19 specific and may have overlaps with many other disease processes. Increased radiation exposure should also be considered, especially in younger patients. However, when CT images were used as an adjunctive tool in the diagnosis and/or follow-up of COVID-19 patients, we think that examining changes in density of the lesions might provide prognostic data and might prevent unnecessary follow-up CTs to be performed to observe the complete resolution of the lesions.

Sun and colleagues found significant correlations between clinical features and quantitative CT parameters, including GGO, consolidation and total lesion score. Matos and coworkers also showed that lymphocyte percentage and CRP could predict the median volume of the chest CT lesions in COVID-19. However, the authors did not study the relationship between lesion density and laboratory features. In contrast, no significant correlation could be found between the admission chest CT density and presentation symptoms such as fever, dyspnea and cough. The relatively small sample size of the current study might have caused this result.

Some limitations of the current study are worthy of mention. First, the study sample size is relatively small. Second, COVID-19 patients whose chest CT findings persisted or worsened despite clinical improvement were selected. Thus, the findings of this study can only be applied to this rather specific subpopulation of COVID-19 patients. Third, data regarding the timing of the symptom onset in COVID-19 patients were not obtained. Symptoms to admission times may differ among the patients. And symptoms and laboratory values might have changed because of this.

In conclusion, despite the aforementioned limitations, this study was the first in the literature reporting that reduction in chest CT lesion densities correlated with clinical and laboratory improvement in patients hospitalised because of COVID-19. Particularly in patients whose lesions in chest CT seems persistent or worsening despite
clinical and laboratory improvement, chest CT density reduction might point to the future resolution of the lung lesions and may preclude unnecessarily long hospitalisations in this patient population. This is of practical importance considering the limited inpatient bed capacities in some parts of the world.

**DISCLOSURES**
No conflict of interest.

**DATA AVAILABILITY STATEMENT**
Data used in this study are included in the manuscript.

**ORCID**
Isil Yurdaisik https://orcid.org/0000-0001-8316-1229
Suleyman Hilmi Aksoy https://orcid.org/0000-0002-2356-0268

**REFERENCES**
1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
2. El Homsi M, Chung M, Bernheim A, et al. Review of chest CT manifestations of COVID-19 infection. Eur J Radiol Open. 2020;7:100239. https://doi.org/10.1016/j.ejro.2020.100239
3. Zhao W, Zhong Z, Xie X, et al. Relation between chest CT findings and clinical conditions of coronavirus disease (COVID-19) pneumonia: a multicenter study. Am J Roentgenol. 2020;214:1072-1077. https://doi.org/10.2214/AJR.20.22976
4. Xie X, Zhong Z, Zhao W, et al. Chest CT for typical coronavirus disease 2019 (COVID-19) pneumonia: relationship to negative RT-PCR testing. Radiology. 2020;296:E41-E45. https://doi.org/10.1148/radiol.2020200343
5. Huang P, Liu T, Huang L, et al. Use of chest CT in combination with negative RT-PCR assay for the 2019 novel coronavirus but high clinical suspicion. Radiology. 2020;295:22-23. https://doi.org/10.1148/radiol.2020200330
6. Li X, Zeng W, Li X, et al. CT imaging changes of coronavirus disease 2019 (COVID-19): a multicenter study in Southwest China. J Transl Med. 2020;18:154. https://doi.org/10.1186/s12967-020-02324-w
7. Bao C, Liu X, Zhang H, et al. Coronavirus disease 2019 (COVID-19) CT findings: a systematic review and meta-analysis. J Am Coll Radiol. 2020;17:701-709. https://doi.org/10.1016/j.jacr.2020.03.006
8. Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296:E115-E117. https://doi.org/10.1148/radiol.2020200432
9. Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020;295:715-721. https://doi.org/10.1148/radiol.2020200370
10. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020;295:200463. https://doi.org/10.1148/radiol.2020200463
11. Wang Y, Dong C, Hu Y, et al. Temporal changes of CT findings in 90 patients with COVID-19 pneumonia: a longitudinal study. Radiology. 2020;296:E55-E64. https://doi.org/10.1148/radiol.2020200843
12. Wang Y, Chen Y, Wei Y, et al. Quantitative analysis of chest CT imaging findings with the risk of ARDS in COVID-19 patients: a preliminary study. Ann Transl Med. 2020;8:594. https://doi.org/10.21037/atm-20-3554
13. Du S, Gao S, Huang G, et al. Chest lesion CT radiological features and quantitative analysis in RT-PCR turned negative and clinical symptoms resolved COVID-19 patients. Quant Imaging Med Surg. 2020;10:1307-1317. https://doi.org/10.21037/qims-20-531
14. Li K, Fang Y, Li W, et al. CT image visual quantitative evaluation and clinical classification of coronavirus disease (COVID-19). Eur Radiol. 2020;30:4407-4416. https://doi.org/10.1007/s00330-020-06817-6
15. Zhou S, Wang Y, Zhu T, et al. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. Am J Roentgenol. 2020;214:1287-1294. https://doi.org/10.2214/AJR.20.22975
16. Sun Z, Zhang N, Li Y, et al. A systematic review of chest imaging findings in COVID-19. Quant Imaging Med Surg. 2020;10:1058-1079. https://doi.org/10.21037/qims-20-564
17. Mehrabi S, Fontana S, Mambrin F, et al. Pitfalls of computed tomography in the coronavirus 2019 (COVID-19) era: a new perspective on ground-glass opacities. Cureus. 2020;12:e8151. https://doi.org/10.7759/cureus.8151
18. Sun D, Li X, Guo D, et al. CT quantitative analysis and its relationship with clinical features for assessing the severity of patients with COVID-19. Korean J Radiol. 2020;21:859-868 https://doi.org/10.3348/kjr.2020.0293
19. Matos J, Paparo F, Mussetto I, et al. Evaluation of novel coronavirus disease (COVID-19) using quantitative lung CT and clinical data: prediction of short-term outcome. Eur Radiol Exp. 2020;4:39. https://doi.org/10.1186/s41747-020-00167-0

How to cite this article: Yurdaisik I, Nurili F, Agirman AG, Aksoy SH. The relationship between lesion density change in chest computed tomography and clinical improvement in COVID-19 patients. Int J Clin Pract. 2021;00:e14355. https://doi.org/10.1111/ijcp.14355